Proteon Therapeutics Appoints Scott Toner as Senior Vice President of Marketing
02 juin 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 2, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics to Present at Upcoming ERA-EDTA Annual Congress
22 mai 2015 07h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces First Quarter 2015 Financial Results
13 mai 2015 17h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at Two International Vascular Access Conferences
13 avr. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study of Investigational New Drug Vonapanitase in Chronic Kidney Disease Patients Undergoing Surgical Creation of an Arteriovenous Fistula for Hemodialysis
26 mars 2015 19h00 HE
|
Proteon Therapeutics, Inc.
DALLAS and WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results
20 mars 2015 07h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 20, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference on March 4th
26 févr. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Ring the Nasdaq Stock Market Opening Bell on February 9th
06 févr. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference February 9th
05 févr. 2015 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
08 janv. 2015 16h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...